© 2023 MJH Life Sciences™ and Nutritional Outlook. All rights reserved.
Animal and in vitro models show that the combination of Eucommia, Cuscuta, and Drynaria can support bone health by reducing the prevalence of osteclasts, which contain bone dissolving proteins.
A recent study1 found that the combination of Eucommia, Cuscuta, and Drynaria (EuBone from Chenland, based in Irvine, CA), which are widely used in traditional Chinese medicine, improved bone density, structural integrity, and biochemical function in rats with Glucocorticoid-induced osteoporosis (GIO). Administration also resulted in reduced urinal calcium, phosphorus loss, and decreased expression of RANKL (Receptor activator of nuclear factor kappa-Β ligand), CTX (cross-linked C-telopeptide of type I collagen) in serum, increased serum calcium, phosphorus, and OPG (Osteoprotegerin) level. In vitro, the combination reduced the prevalence of osteoclasts, which are bone dissolving proteins, pointing to the potential mechanism of action.
Given the promising results from in vitro and animal models Chenland is underway with a double-blind, placebo-controlled study on bone health in post-menopausal women, which is expected to be completed in 2023, and is planning a 180-day, single-center, open label human clinical study to investigate the effects of EuBone on elderly adults (especially women) with mild to moderate osteoporosis.